Laurence Hicks - 27 Sep 2021 Form 3 Insider Report for Arch Therapeutics, Inc. (ARTHQ)

Role
Director
Signature
/s/ Laurence Hicks
Issuer symbol
ARTHQ
Transactions as of
27 Sep 2021
Net transactions value
$0
Form type
3
Filing time
12 Oct 2021, 21:23:12 UTC
Next filing
08 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ARTH Common Stock 27,273 27 Sep 2021 Drake Partners Equity LLC F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ARTH Stock Option (Right to Buy) 27 Sep 2021 Common Stock 250,000 $0.1028 Direct F2
holding ARTH Stock Option (Right to Buy) 27 Sep 2021 Common Stock 150,000 $0.1250 Hicks Family LLC F1, F3
holding ARTH Stock Option (Right to Buy) 27 Sep 2021 Common Stock 100,000 $0.1900 Hicks Family LLC F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reporting person may be deemed to be a control person of this entity.
F2 The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 36 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable.
F3 The option was granted pursuant to the Plan. The option vests equally on each of the first four three-month anniversaries of the grant date.